We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: 3:30:01 PM GMT+5:30 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Combining antihypertensives with lipid-lowering medications, diuretics, or oral anticoagulants for 5 ... “Antiplatelets stood out as the single drug class that seems to be harmful for cognition ...

Use of Anticoagulant Drug After Aortic Valve Replacement Lowers Mortality Risk Dec. 7, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

At close: 3:29:49 PM GMT+5:30 ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

The Central Board of Secondary Education has issued the CBSE Board Exam 2025 datesheets today, November 20, 2024.Students can access the CBSE Class 10th Date Sheet 2025 on the official website ...

Anticoagulants (warfarin, heparin and a newer class of drugs called direct oral anticoagulants) work by interfering with proteins involved in the clotting process. Doctors prescribe them to dissolve ...

Dutch biopharma Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy ... Merus' drug achieved an objective response ...

a) Any publication of Bureau tide predictions must acknowledge copyright in the Material in the Commonwealth of Australia represented by the Bureau of Meteorology and must include the following ...